Tech Company Financing Transactions
Semafore Pharmaceuticals Funding Round
On 1/5/2007, Semafore Pharmaceuticals landed $9.5 million in Series B funding from Twilight Venture Partners.
Transaction Overview
Company Name
Announced On
1/5/2007
Transaction Type
Venture Equity
Amount
$9,500,000
Round
Series B
Investors
Twilight Venture Partners (Ronald Henriksen)
Proceeds Purpose
Proceeds from the financing will be used to advance Semafore's
clinical program for SF1126, its lead PI3 Kinase inhibitor for the
treatment of cancer, to further develop the company's pipeline of agents
targeting the PI3K and PTEN pathway, and for general corporate purposes.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
17338 Westfield Park Road 3
Westfield, IN 46074
USA
Westfield, IN 46074
USA
Phone
Website
Email Address
Overview
Semafore is a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway, one of the most promising target pathways for multiple disorders, including the company's focus--cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Becker
Chief Operating Officer
John Sima
Chief Scientific Officer
Joseph Garlich
Browse more venture capital transactions:
Prev: 1/5/2007: vMix Media venture capital transaction
Next: 1/5/2007: Synosia Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs